Pfizer (NYSE:PFE) Trading 2.1% Higher – Still a Buy?

Pfizer Inc. (NYSE:PFE) shares were up 2.1% on Wednesday . The company traded as high as $24.82 and last traded at $24.7710. 44,094,280 shares were traded during trading, an increase of 3% from the average daily volume of 42,613,000 shares. The stock had previously closed at $24.25.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced FDA approval for PADCEV plus Keytruda in muscle-invasive bladder cancer, expanding the regimen as both neoadjuvant and adjuvant therapy and potentially opening the treatment to a wider patient population. Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC
• Positive Sentiment: Recent commentary has highlighted Pfizer’s oncology growth story, including sales from key cancer drugs, biosimilars, and pipeline updates that may help offset declines in older products. Here’s How Pfizer’s Oncology Growth Story Looks Ahead of Q2 Results
• Positive Sentiment: Several articles pointed to Pfizer’s shares trading below Wall Street’s consensus target, framing the stock as potentially undervalued and attractive for income-focused investors due to its high dividend yield. Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?
• Neutral Sentiment: Market coverage noted that Pfizer has been advancing while the broader market was weaker, but this was more of a trading snapshot than a new company-specific catalyst. Pfizer (PFE) Advances While Market Declines: Some Information for Investors
• Negative Sentiment: Some recent pieces flagged lingering bearish technical signals and warned that Wall Street still expects a double-digit decline in next quarter’s profit, which may keep a lid on enthusiasm. Here’s What to Expect From Pfizer’s Next Earnings Report

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on PFE. UBS Group reissued a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Guggenheim decreased their target price on Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday. Wolfe Research restated an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. Finally, Morgan Stanley upped their price target on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.50.

Pfizer Stock Performance

The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The business’s 50-day moving average is $25.28 and its 200-day moving average is $26.18. The company has a market capitalization of $141.18 billion, a PE ratio of 18.91 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the prior year, the company earned $0.92 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Institutional Investors Weigh In On Pfizer

Institutional investors have recently modified their holdings of the stock. Brighton Jones LLC lifted its stake in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank raised its holdings in Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares during the last quarter. Sei Investments Co. lifted its position in Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after acquiring an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC lifted its position in Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after acquiring an additional 31,896 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.